Document:

EX-10.3

 Exhibit 10.3 

September 7, 2015 
 Mr. Konstantinos Alataris 

Dear Konstantinos: 
 This letter will confirm
the terms and conditions of your employment with ZP Opco, Inc., a Delaware corporation (the “Company”) and wholly owned subsidiary of Zosano Pharma Corporation, a Delaware corporation (the “Parent”).

 1. Position and Duties. Effective September 21, 2015 (the “Start Date”), you will be elected as the
President of the Parent and the President and Chief Operating Officer of the Company. You will report to the Chief Executive Officer of the Parent (the “CEO”). Like other officers of the Parent, you will be a full-time
employee of the Company. You agree to perform the duties of your positions and such other duties as may reasonably be assigned to you from time to time by the CEO. You also agree that, while employed by the Company, you will devote your full
business time and your best efforts, business judgment, skill and knowledge to the advancement of the business and interests of the Parent, the Company and their respective Affiliates (as defined in Section 6) and to the discharge of your
duties and responsibilities for them. 
 2. Compensation and Benefits. During your employment, as compensation for the services
performed by you for the Company and its Affiliates, the Company will provide you the following pay and benefits: 
 (a) Base Salary.
The Company will pay you a base salary at the rate of $375,000 per year, payable in accordance with the regular payroll practices of the Company and subject to increase from time to time by the Compensation Committee of the Board (the
“Compensation Committee”) in its discretion. 
 (b) Bonus Compensation. During employment, you will be
considered annually for a bonus target of 30% of your base salary. The amount of any bonus awarded, whether in cash or stock, will be determined by the Compensation Committee in its discretion, after consideration of a proposal from the CEO, and
will be based on (i) your performance and the performance of the Company against goals established annually and (ii) the terms and conditions of the Parent’s employee bonus program, adopted by the Compensation Committee on
February 27, 2015. 
 (c) Stock Options. The Compensation Committee shall grant you, under Parent’s Amended and Restated
2014 Equity and Incentive Plan, an incentive stock option to purchase 209,394 shares of common stock, $0.0001 par value per share, of Parent (“Common Stock”). Such stock option shall (A) have an exercise price per share equal
to the closing price per share of Common Stock on the date of the grant, and (B) be subject to vesting requirements such that 25% of the total option shares shall vest on first anniversary of the date of grant and

 Mr. Konstantinos Alataris 

September 7, 2015 
  Page
 2
 
  

 
an additional 2.0833% of the total option shares shall vest thereafter on the monthly anniversary of such date; provided, however, that 18.75% of the total option shares (in addition to
any then-vested option shares) shall vest upon termination of employment pursuant to the last sentence of Section 4(a) or the first sentence of Section 4(b); provided, further, that 100% of any then unvested option shares shall vest
upon a Constructive Termination Event (as defined in Section 5(b)). 
 (d) Participation in Employee Benefit Plans. You shall be
entitled to participate in any and all employee benefit plans from time to time in effect for the full-time employees of the Company generally, but the Company shall not be required to establish any such program or plan. Such participation shall be
subject to (i) the terms of the applicable plan documents and (ii) generally applicable Company policies. The Company may alter, modify, add to or delete its employee benefit plans at any time as it, in its sole discretion, determines to
be appropriate. 
 (e) Vacations. You will be entitled to three weeks of paid vacation per year, in addition to holidays observed by
the Company. Vacation may be taken at such times and intervals as you shall determine, subject to the reasonable business needs of the Company. 

(f) Business Expenses. The Company will pay or reimburse you for all reasonable business expenses incurred or paid by you in the
performance of your duties and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such expenses set by the Company and to such reasonable substantiation and documentation as it may specify from time to
time. 
 3. Confidential Information and Restricted Activities. 

(a) Confidential Information. During the course of your employment with the Company, you will learn of Confidential Information (as
defined in Section 6), and you may develop Confidential Information on behalf of the Company. You agree that you will not use or disclose to any Person (as defined in Section 6) any Confidential Information obtained by you incident to your
employment or any other association with the Company or any of its Affiliates, except as required by applicable law or for the proper performance of your regular duties and responsibilities for the Company. You understand that this restriction shall
continue to apply for three (3) years after your employment terminates, regardless of the reason for such termination. In addition, you agree to sign the Company’s standard form of invention assignment agreement as a condition of your
employment hereunder. 
 (b) Protection of Documents. All documents, records and files, in any media of whatever kind and
description, relating to the business, present or otherwise, of the Parent, the Company or any of their respective Affiliates, and any copies, in whole or in part, thereof (the “Documents”), whether or not prepared by you, shall be
the sole and exclusive property of the Company. You agree to safeguard all Documents and to surrender to the Company, at the time your employment terminates or at such earlier time or times as the CEO may specify, all Documents then in your
possession or control. 

 Mr. Konstantinos Alataris 

September 7, 2015 
  Page
 3
 
  
 (c)
Non-Solicitation. You acknowledge that in your employment with the Company you will have access to Confidential Information which, if disclosed, would assist in competition against the Company and its Affiliates, and that you will also
generate good will for the Company and its Affiliates in the course of your employment. Therefore, you agree that the following restrictions on your activities during and after the termination of your employment are necessary to protect the good
will, Confidential Information and other legitimate interests of the Company and its Affiliates: While you are employed by the Company and during the 12 months immediately following termination of your employment for whatever reason, you shall not,
directly or through any other Person, (A) seek to persuade any employee of the Company or any of its Affiliates to discontinue employment or (B) solicit or encourage any customer, distributor, vendor, or other business partner of the
Company or any of its Affiliates or any independent contractor providing services to the Company or any of its Affiliates to terminate or diminish its relationship with them. For purposes of the foregoing, the terms “employee,”
“customer,” “distributor,” and “vendor” shall also include any person or party who held such status during the immediately preceding six (6) months. 

(d) Enforcement of Restrictions. In signing this letter agreement, you give the Company assurance that you have carefully read and
considered all the terms and conditions of this letter agreement, including the restraints imposed on you under this Section 3. You agree without reservation that these restraints are necessary for the reasonable and proper protection of the Company
and its Affiliates, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area. You further agree that, were you to breach any of the covenants contained in this Section 3, the
damage to the Company and its Affiliates would be irreparable. You therefore agree that the Company, in addition to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened
breach by you of any of those covenants, without having to post bond. You also agree that the period of restriction in Section 3(c) shall be tolled and shall not run during any period you are in violation thereof. You and the Company further agree
that, in the event that any provision of this Section 3 is determined by any court of competent jurisdiction to be unenforceable by reason of its being extended over too great a time, too large a geographic area or too great a range of
activities, that provision shall be deemed to be modified to permit its enforcement to the maximum extent permitted by law. It is also agreed that each of the Company’s Affiliates shall have the right to enforce all of your obligations to that
Affiliate under this letter agreement, including without limitation pursuant to this Section 3. It is agreed and understood that the terms of this letter agreement are severable, and that no breach of any provision of this letter agreement or
any other purported violation of law by the Company shall operate to excuse you from the performance of your obligations under this Section 3. 

4. Termination of Employment. Your employment under this letter agreement shall continue for no definite term until terminated pursuant
to this Section 4. 
 (a) The Company may terminate your employment for Cause upon notice to you setting forth in reasonable detail the
nature of the Cause (as defined below). The 

 Mr. Konstantinos Alataris 

September 7, 2015 
  Page
 4
 
  

 
following, as determined by the Company in its reasonable judgment, shall constitute “Cause” for termination: (i) your persistent and willful refusal to follow reasonable
directives of the CEO; (ii) gross negligence or willful misconduct in the performance of your duties and responsibilities to the Company or any of its Affiliates; (iii) your material breach of this letter agreement or any other agreement
between you and the Company or any of its Affiliates, which breach continues for more than 15 days after the Company gives you written notice which sets forth in reasonable detail the nature of such breach; or (iv) other conduct by you that is
or could reasonably anticipated to be materially harmful to the business, interests or reputation of the Company or any of its Affiliates. The Company also may terminate your employment other than for Cause upon written notice to you. 

(b) You may terminate your employment for Good Reason (as defined below) upon notice to the Company setting forth in reasonable detail the
nature of the Good Reason. The following shall constitute “Good Reason” for termination: (i) the Company’s failure to continue you in the position of President and Chief Operating Officer of the Company with such duties
typically associated with such position, or (ii) material failure of the Company to provide you compensation and benefits in accordance with the terms of Section 2, above, for more than ten (10) business days after notice from you
specifying in reasonable detail the nature of such failure, except in connection with a decrease in salary affecting each senior management employee of the Company in a proportionate manner, or (iii) relocation of your principal place of
employment to a location other than the greater San Francisco Bay area, California. You may also terminate your employment other than for Good Reason upon 30 days’ written notice to the Company. 

(c) In the event you become disabled during employment and, as a result, are unable to continue to perform substantially all of your duties
and responsibilities under this letter agreement, either with or without reasonable accommodation, the Company will continue to pay you your base salary and to provide you benefits in accordance with Section 2(d) above, to the extent permitted
by plan terms, for up to twelve (12) weeks of disability during any period of three hundred and sixty-five (365) consecutive calendar days. If you are unable to return to work after twelve (12) weeks of disability, the Company may
terminate your employment, upon notice to you. If any question shall arise as to whether you are disabled to the extent that you are unable to perform substantially all of your duties and responsibilities for the Company and its Affiliates, you
shall, at the Company’s request, submit to a medical examination by a physician selected by the Company to whom you or your guardian, if any, has no reasonable objection to determine whether you are so disabled, and such determination shall for
the purposes of this letter agreement be conclusive of the issue. If such a question arises and you fail to submit to the requested medical examination, the Company’s determination of the issue shall be binding on you. 

5. Severance Payments and Other Matters Related to Termination. 

(a) Involuntary Termination. In the event of termination of your employment by the Company other than for Cause, or in the event of
your termination of employment for Good Reason, the Company will (i) continue to pay you your base salary for a 

 Mr. Konstantinos Alataris 

September 7, 2015 
  Page
 5
 
  

 
period of nine (9) months from and after the date of termination, (ii) pay you an amount equal to the lesser of (x) the target bonus of 30% of your base salary pro rata for such
nine (9) months or (y) the amount of the annual bonus awarded to you in respect of the prior year pro rata for nine (9) months, such bonus severance to be paid in equal installments during the nine (9)- month period following the date
of termination, and (iii) continue to provide you with group health and dental plan benefits for a period of nine (9) months from and after the date of termination, with the cost of the regular premiums for such benefits shared in the same
relative proportion by the Company and you as in effect on the date of termination. The Company will also pay you on the date of termination any base salary earned but not paid through the date of termination, and pay for any vacation time accrued
but not used to that date. In addition, as provided in Section 2(c), the vesting schedule for any stock options outstanding on the date of termination will automatically accelerate so that 18.75% of the total option shares shall immediately
vest and become exercisable upon such termination. Except as set forth in clause (ii) and (iii) of the first sentence of this Section 5(a), benefits shall terminate in accordance with the terms of the applicable benefit plans based on
the date of termination of your employment. 
 (b) Involuntary Termination within One Year after Change in Control. In the event of
termination of your employment by the Company (or its successor) other than for Cause, or in the event of your termination of employment for Good Reason, in either case during the one (1)-year period following a Change in Control (a
“Constructive Termination Event”), the Company (or its successor) will, in lieu of any severance under Section 5(a) above, (i) continue to pay you your base salary for a period of nine (9) months from and after the
date of termination, (ii) pay you an amount equal to the lesser of (x) the target bonus of 30% of your base salary pro rata for such nine (9) months or (y) the amount of the annual bonus awarded to you in respect of the prior
year pro rata for nine (9) months, such bonus severance to be paid in equal installments during the nine (9)-month period following the date of termination, and (iii) continue to provide you with group health and dental plan benefits for a
period of nine (9) months from and after the date of termination, with the cost of all regular premiums for such benefits paid by the Company. The Company will also pay you on the date of termination any base salary earned but not paid through
the date of termination, and pay for any vacation time accrued but not used to that date. In addition, as provided in Section 2(c), the vesting schedule for any stock options outstanding on the date of termination will automatically accelerate
so that 100% of any then unvested option shares shall immediately vest and become exercisable upon such termination. Except as set forth in clause (ii) and (iii) of the first sentence of this Section 5(b), benefits shall terminate in
accordance with the terms of the applicable benefit plans based on the date of termination of your employment. 
 (c) Severance
Conditional Upon Release. Any obligation of the Company to provide you severance payments under Sections 5(a) and 5(b) above shall be conditioned upon your signing a general release of claims in the form provided by the Company and reasonably
acceptable to you (the “Employee Release”) within twenty-one (21) days after the date on which you give or receive, as applicable, notice of termination of your employment and upon your not revoking the Employee Release
thereafter. All base salary and bonus severance payments will be payable in accordance with the normal payroll practices of the Company, and 

 Mr. Konstantinos Alataris 

September 7, 2015 
  Page
 6
 
  

 
will begin at the Company’s next regular payroll period following the effective date of the Employee Release, but shall be retroactive to the date of termination. For the avoidance of doubt,
no cash compensation that may be earned by you pursuant to employment or a consulting arrangement with a Person other than the Company during the period of time that the Company (or its successor) is making payments to you pursuant to this
Section 5 shall be credited toward the Company’s severance obligations under this Section 5. Notwithstanding anything to the contrary contained in this letter agreement, in the event that at the time of your separation from service
you are a “specified employee,” as hereinafter defined, any and all amounts payable under this Section 5 in connection with such separation from service that constitute deferred compensation subject to Section 409A of the
Internal Revenue Code of 
 1986, as amended (“Section 409A”), as determined by the Company in its sole discretion, and that would (but for
this sentence) be payable within six (6) months following such separation from service, shall instead be paid on the date that follows the date of such separation from service by six (6) months. For purposes of the preceding sentence,
“separation from service” shall be determined in a manner consistent with subsection (a)(2)(A)(i) of Section 409A and the term “specified employee” shall mean an individual determined by the Company to be a
specified employee as defined in subsection (a)(2)(B)(i) of Section 409A. 
 (d) Termination for Cause or Voluntary Termination.
In the event of termination of your employment by the Company for Cause or your termination other than for Good Reason, the Company will pay you any base salary earned but not paid through the date of termination and pay for any vacation time
accrued but not used to that date. The Company shall have no obligation to pay you any bonus compensation or severance payments. Except for any right you may have under the federal law known as “COBRA” to continue participation in the
Company’s group health and dental plans at your cost, benefits shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of your employment. 

(e) Survival of Certain Provisions. Provisions of this letter agreement shall survive any termination if so provided in this letter
agreement or if necessary or desirable to accomplish the purposes of other surviving provisions, including without limitation your obligations under Section 3 of this letter agreement. The obligation of the Company to make severance payments to
you under Section 5(a) or 5(b) above, and your right to retain such payments, are expressly conditioned upon your continued full performance of your obligations under Section 3 hereof. Upon termination by either you or the Company, all
rights, duties and obligations of you and the Company to each other shall cease, except as otherwise expressly provided in this letter agreement. 

6. Definitions. For purposes of this letter agreement, the following definitions apply: 

“Affiliates” means all persons and entities directly or indirectly controlling, controlled by or under common control with
the Company, where control may be by management authority, equity interest or otherwise. 

 Mr. Konstantinos Alataris 

September 7, 2015 
  Page
 7
 
  
 “Confidential
Information” means any and all information of the Company and its Affiliates that is not generally available to the public. Confidential Information also includes any information received by the Company or any of its Affiliates from any
Person with any understanding, express or implied, that it will not be disclosed. Confidential Information does not include information that enters the public domain, other than through your breach of your obligations under this letter agreement.

 “Change in Control” ” means (A) the sale, lease, exchange, transfer or other disposition of all or
substantially all of the assets of the Company and its Affiliates, or (B) any merger, consolidation or other business combination or stock sale (other than a sale of stock for capital raising purposes) that results in the holders of the
outstanding voting securities of the Company or Parent immediately prior to such transaction beneficially owning or controlling immediately after such transaction less than a majority of the voting securities of the Company or Parent, respectively,
or the surviving entity or the entity that controls such surviving entity. 
 “Person” means an individual, a corporation,
a limited liability company, an association, a partnership, an estate, a trust or any other entity or organization, other than the Company or any of its Affiliates. 

7. Conflicting Agreements. You hereby represent and warrant that your signing of this letter agreement and the performance of your
obligations under it will not breach or be in conflict with any other agreement to which you are a party or are bound, and that you are not now subject to any covenants against competition or similar covenants or any court orders that could affect
the performance of your obligations under this letter agreement. You agree that 
 you will not disclose to or use on behalf of the Company
any proprietary information of a third party without that party’s consent. 
 8. Withholding. All payments made by the Company
under this letter agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law. 
 9.
Assignment. Neither you, the Company nor Parent may make any assignment of this letter agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other parties; provided, however, that
each of the Company and Parent may assign its rights and obligations under this letter agreement without your consent to one of its Affiliates or to any Person with whom it shall hereafter effect a reorganization, consolidate with, or merge into or
to whom it transfers all or substantially all of its properties or assets. 
 This letter agreement shall inure to the benefit of and be
binding upon you, the Company and Parent, and each of our respective successors, executors, administrators, heirs and permitted assigns. 

10. Severability. If any portion or provision of this letter agreement shall to any extent be declared illegal or unenforceable by a
court of competent jurisdiction, then the 

 Mr. Konstantinos Alataris 

September 7, 2015 
  Page
 8
 
  

 
remainder of this letter agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected
thereby, and each portion and provision of this letter agreement shall be valid and enforceable to the fullest extent permitted by law. 

11. Miscellaneous. This letter agreement sets forth the entire agreement between you and the Company and replaces all prior and
contemporaneous communications, agreements and understandings, written or oral, with respect to the terms and conditions of your employment with the Company. This letter agreement may not be modified or amended, and no breach shall be deemed to be
waived, unless agreed to in writing by you and the Company. The headings and captions in this letter agreement are for convenience only and in no way define or describe the scope or content of any provision of this letter agreement. The words
“include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation.” This letter agreement may be executed in two or more
counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument. This is a California contract and shall be governed and construed in accordance with the laws of the State of California,
without regard to the conflict of laws principles thereof. 
 12. Notices. Any notices provided for in this letter agreement shall be
in writing and shall be effective when delivered in person or deposited in the United States mail, postage prepaid, and addressed to you at your last known address on the books of the Company or, in the case of the Company, to it at its principal
place of business, or to such other address as either party may specify by notice to the other actually received. 

*  *  *  *  * 

 At the time this letter agreement is signed by you and on behalf of the Company and Parent, it
will take effect as a binding agreement among you, the Company and Parent on the basis set forth above. 
  

									
	ZOSANO PHAMRAM CORPORATION	 		 	EMPLOYEE:
					
	By:	 	 /s/ Vikram
Lamba                                    
	 		 	By:	 	 /s/ Konstantinos Alataris

		 	Name: Vikram Lamba	 		 		 	Konstantinos Alataris
		 	Title: Chief Executive Officer	 		 		 	
	Date signed: September 7, 2015	 		 	Date signed: September 6, 2015
				
	ZP OPCO, Inc.	 		 		 	
					
	By:	 	 /s/ Vikram Lamba
	 		 		 	
		 	Name: Vikram Lamba	 		 		 	
		 	Title: Chief Executive Officer	 		 		 	
	Date signed: September 7, 2015EX-10.4

 Exhibit 10.4 
  

 
 SCIENTIFIC ADVISOR AGREEMENT 

THIS SCIENTIFIC ADVISOR AGREEMENT (this
“Agreement”) is made and entered into as of December 31, 2015 (the “Effective Date”), by and among Zosano Pharma Corporation, a Delaware corporation having its principal place of business
at 34790 Ardentech Court, Fremont, California 94555 (the “Parent”), ZP Opco, Inc., a Delaware corporation and wholly owned subsidiary of Parent (the “Company”), and PETER
DADDONA, an individual residing at 35 Anderson Way, Menlo Park, California 94025 (the “Advisor”). The Parent, Company and Advisor may be referred to herein individually as a
“Party” or collectively as the “Parties.” 
 Recitals 

WHEREAS, the Advisor is currently a director of the Parent, an employee of the Company and the Chief
Scientific Officer of both the Parent and the Company; 
 WHEREAS, the Advisor desires (i) to
resign as an employee of the Company and as an officer of the Parent and the Company, effective as of the Effective Date; and (ii) commencing on January 1, 2016, to provide scientific advisory services to the Company subject to the term
and conditions set forth herein; 
 WHEREAS, the Company desires to retain Advisor to provide
scientific advisory services subject to the terms and conditions set forth herein; 
 WHEREAS, the
Advisor desires to continue to serve as a director of the Parent in accordance with the bylaws of the Parent; 
 NOW
THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties hereby agree as follows: 

1. Scientific Advisory Services. 

1.1 As further provided in Section 9.2, effective as of the Effective Date, the Advisor hereby resigns as an employee and officer of the
Company and as an officer of the Parent. 
 1.2 Commencing on January 1, 2016 (the “Start Date”), the Company
hereby retains Advisor, and Advisor hereby agrees to perform such scientific advisory services for the Company as set forth in Section 1 of Exhibit A (collectively, the “Services”). Advisor shall report to the
Parent’s Chief Executive Officer or, if requested to do so by the Chief Executive Officer, report to the Parent’s Chief Scientific Officer. The specific nature and amount of the Services shall be as determined by the Company during the
term of this Agreement; provided, however, that Advisor agrees that during the Term (as defined in Section 9.1 below), Advisor shall be available to provide Services, either in person or via telephone at the Company’s discretion, on
two days of each month, subject to reasonable advance notice by the Company, for four hours on each day (for a total of eight hours per month). Advisor agrees to perform the Services, and provide the results thereof, with the highest degree of
professional skill and expertise. Advisor may use the assistance of other individuals who are not employees of the Company only with the prior written consent of the Company. 

 1.3 For the avoidance of doubt, the Advisor acknowledges that he is currently a director of the
Parent and will continue to serve as a director of the Parent, in accordance with the Parent’s bylaws, until the earliest of his death, resignation (as a director), or removal. Advisor acknowledges that he will not qualify as an
“independent director” within the meaning of NASDAQ listing rule 5605(a)(2) and will not be eligible for any of the compensation that the Parent pays to its independent directors. 

2. Compensation. 

Section 2 of Exhibit A attached hereto sets forth the amount and timing of payment for the Services and reimbursable expenses. The
Company will reimburse Advisor for expenses actually incurred by Advisor in performing the Services, including but not limited to travel and accommodation expenses, so long as such expenses are reasonable and necessary as determined by the Company
and approved in advance by Company. Advisor shall maintain adequate books and records relating to any expenses to be reimbursed and shall submit requests for reimbursement in a timely manner and form acceptable to the Company. 

3. Independent Contractor. 

The Parties understand and agree that Advisor is an independent contractor and not an agent or employee of the Company. Advisor has no
authority to obligate the Company by contract or otherwise. Advisor will not be eligible for any employee benefits, nor will the Company make deductions from Advisor’s fees for taxes or insurance (except as otherwise required by applicable law
or regulation). Any payroll and employment taxes, insurance, and benefits imposed on Advisor due to activities performed hereunder will be the sole responsibility of Advisor. 

4. Recognition of Company’s Rights; Nondisclosure. 

Advisor recognizes that the Company is engaged in a continuous program of research and development respecting its present and future business
activities. Advisor agrees as follows: 
 4.1 At all times during the term of Advisor’s association with the Company and thereafter,
Advisor will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information (defined below), except to the extent such disclosure, use or publication may be required in direct
connection with Advisor’s performing requested Services for the Company or is expressly authorized in writing by an officer of the Company. It is understood that the Proprietary Information will remain the sole property of the Company. Advisor
further agrees to take all reasonable precautions to prevent any unauthorized disclosure of the Proprietary Information including, but not limited to, having each employee, agent or representative of Advisor, if any, with access to any Proprietary
Information execute a nondisclosure agreement containing provisions in the Company’s favor substantially similar to Sections 4 and 13 of this Agreement. 

4.2 The term “Proprietary Information” shall mean any and all trade secrets, confidential knowledge, know-how, data or
other proprietary information or materials of the Company, the Parent or any of their respective affiliates. By way of illustration but not limitation, Proprietary Information includes: (i) inventions, ideas, samples, prototypes, devices,
hardware, software, electronic components and materials, and procedures for producing any such 

 
items, as well as data, know-how, improvements, inventions, discoveries, developments, designs and techniques; (ii) information regarding plans for research, development, new products,
marketing and selling activities, business models, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (iii) information regarding the skills and compensation of employees or consultants of the
Company. 
 4.3 In addition, Advisor understands that the Company has received and in the future will receive from third parties
confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the
term of Advisor’s association with the Company and thereafter, Advisor will hold Third Party Information in the strictest confidence and will not disclose or use Third Party Information, except in connection with Advisor’s performing
requested Services for the Company, or as expressly authorized in writing by an officer of the Company. 
 5. Intellectual Property
Rights. 
 5.1 Advisor shall promptly and fully disclose to the Company any and all ideas, inventions, technologies, discoveries,
improvements, know-how and techniques that the Advisor conceives, reduces to practice or develops during the term of this Agreement, alone or in conjunction with others, and in any way related to or arising from (i) the Company’s Field (as
defined in Section 6.1), (ii) the Services, or (iii) Proprietary Information (collectively, the “Inventions”). Advisor agrees to keep and maintain adequate and current records (in the form of notes, sketches,
drawings or in any other form that may be required by the Company) of all Services provided and results thereof and such records shall be available to and remain the sole property of the Company at all times. Advisor agrees that any and all
Inventions, including any related patents, copyrights, trade secrets and trademark rights, shall be the sole and exclusive property of the Company. 

5.2 Advisor hereby assigns to the Company his entire right, title and interest in and to all Inventions. Advisor hereby designates the Company
as his agent for, and grants to the Company a power of attorney, which power of attorney shall be deemed coupled with an interest, solely for the purpose of effecting the foregoing assignment from the Advisor to the Company. Advisor will perform
other activities necessary to effect the intent of this Section 5.2. 
 5.3 Advisor further agrees to cooperate and provide reasonable
assistance to the Company to obtain and from time to time enforce United States and foreign patents, copyrights, and other rights and protections claiming, covering or relating to the Inventions in any and all countries. 

5.4 Advisor agrees to submit to the Company any proposed publication that contains any discussion relating to the Company, Proprietary
Information, Inventions or work performed by Advisor for the Company hereunder. Advisor further agrees that no such publication shall be made without the prior written consent of the Company, which consent shall not be unreasonably withheld. 

 6. Noncompetition and Nonsolicitation of Employees. 

6.1 During the term of this Agreement, Advisor will not, without the prior consent of the Company’s Board of Directors, engage in any
commercial business activity that competes in any way with any business then being conducted or planned by the Company relating to the research, discovery, development, manufacture or commercialization of transdermal drug delivery systems or patches
for administering pharmaceutical compounds to humans (the “Company’s Field”). 
 6.2 During the term of this
Agreement and for one (1) year after its termination, Advisor will not personally or through others recruit, solicit or induce any employee of the Company to terminate his or her employment with the Company. 

6.3 If any restriction set forth in Sections 6.1 and 6.2 is found by any court of competent jurisdiction to be unenforceable because it
extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be
enforceable. 
 7. No Conflicting Obligation. 

7.1 Advisor represents that Advisor’s performance of all of the terms of this Agreement and the performing of the Services for the Company
do not and will not breach or conflict with any agreement with a third party, including an agreement to keep in confidence any proprietary information of another entity acquired by Advisor in confidence or in trust prior to the date of this
Agreement. 
 7.2 Advisor hereby agrees not to enter into any agreement that conflicts with this Agreement. 

8. No Improper Use of Materials. 

Advisor agrees not to bring to the Company or to use in the performance of Services for the Company any materials or documents of a present or
former employer of Advisor, or any materials or documents obtained by Advisor from a third party under a binder of confidentiality, unless such materials or documents are generally available to the public or Advisor has authorization from such
present or former employer or third party for the possession and unrestricted use of such materials. Advisor understands that Advisor is not to breach any obligation of confidentiality that Advisor has to present or former employers or clients, and
agrees to fulfill all such obligations during the term of this Agreement. 
 9. Term and Termination. 

9.1 Advisor’s Services under this Agreement shall commence on the Effective Date and shall continue for a term of one (1) year from
and after the Effective Date (the “Term”), unless earlier terminated as provided below in this Section 9. Unless earlier terminated as provided below in this Section 9 or otherwise agreed upon in writing by the
Company and Advisor, this Agreement shall automatically terminate upon the expiration of the Term (which, for the avoidance of doubt, is January 1, 2017). 

9.2 Effective December 31, 2015 (the “Resignation Date”), Advisor hereby resigns from his position as Chief
Scientific Officer of the Company and Parent and from any 

 
other positions (excluding director) Advisor may currently hold as a fiduciary of the Company or of Parent. Advisor and the Company hereby acknowledge and agree that the Resignation Date is the
effective date of termination of Advisor’s employment with the Company and its affiliates, and that such resignation is a voluntary termination of employment by Advisor other than for Good Reason pursuant to the last sentence of
Section 4(b) of that certain employment letter agreement dated May 11, 2012 among the Company and Advisor, as amended by the letter amendments thereto dated January 6, 2014, January 16, 2014 and May 29, 2015 (as so
amended, the “Employment Agreement”). In connection with Advisor’s voluntary termination of employment, (i) the Company (x) hereby waives the thirty (30)-day written notice period described in the last sentence
of Section 4(b) of the Employment Agreement and (y) acknowledges its obligations under Section 5(d) of the Employment Agreement to pay Advisor his accrued but unpaid base salary and any accrued but unpaid vacation time, in each case
earned by Advisor while an employee of the Company through the Resignation Date (less applicable taxes and withholding); and (ii) Advisor acknowledges that the Company shall have no obligation to Advisor for any severance payments under the
Employment Agreement and, except for any right Advisor may have under the federal law known as “COBRA” to continue participation in the Company’s group health and dental plans at Advisor’s cost, Advisor’s benefits shall
terminate in accordance with the terms of the applicable benefit plans. In addition, Advisor acknowledges (i) his obligation, in accordance with Section 5(f) of the Employment Agreement, to continue to fully perform following the
Resignation Date Advisor’s obligations under Section 3 of the Employment Agreement and (ii) that the Advisor’s Incentive Stock Option dated June 15, 2012 between the Company and Advisor (the “2012
Option”) will lose its status as an incentive stock option 90 days’ after the Resignation Date and will be treated as a non-qualified stock option from that point forward. For the avoidance of doubt, the 2012 Option will
continue to vest pursuant to the vesting schedule described therein for so long as the Advisor continues to provide Services to the Company or Parent pursuant to this Agreement. 

9.3 Either Party may terminate this Agreement for any reason upon 30 days’ written notice provided to the other Party. 

9.4 The Company will amend the 2012 Option to provide as follows: 

(a) In the event that the Advisor provides Services for the entire Term then Advisor may exercise the 2012 Option at any time prior to
December 31, 2017; 
 (b) In the event that Company terminates this Agreement without cause (e.g., no breach by Advisor) prior to the
expiration of the Term then Advisor may exercise the 2012 Option at any time prior to the first anniversary of the date of termination; and 

(c) In the event that Advisor terminates the Agreement, or if the Company terminates it for cause (e.g., breach by Advisor), prior to the
expiration of the Term then Advisor may exercise the 2012 Option at any time within 90 days after the date of termination. 
 9.5 The
obligations set forth in Sections 4, 5, 6 and 9 through 16 will survive any termination or expiration of this Agreement. Upon termination of this Agreement, Advisor will cease work immediately after giving or receiving such notice of termination,
unless otherwise advised by the Company, and promptly deliver to the Company all documents and other materials of any nature pertaining to the Services, together with all documents and other items containing or pertaining to any Proprietary
Information. 

 10. Assignment. 

The rights and liabilities of the Parties hereto shall bind and inure to the benefit of their respective successors, heirs, executors and
administrators, as the case may be; provided that, as the Company has specifically contracted for Advisor’s Services, Advisor may not assign or delegate Advisor’s obligations under this Agreement either in whole or in part without
the prior written consent of the Company. The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company’s business. Any assignment not in accordance with this
Section 10 shall be void. 
 11. Legal and Equitable Remedies. 

Because Advisor’s Services are personal and unique and because Advisor may have access to and become acquainted with the Proprietary
Information of the Company, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief without prejudice to any other rights and remedies that the Company may
have for a breach of this Agreement. 
 12. Compliance with Applicable Laws and Obligations. 

Advisor will perform the Services in compliance with all applicable laws. 

13. Governing Law; Severability. 

This Agreement shall be governed by and construed according to the laws of the State of Delaware, without regards to conflicts of laws rules.
If any provision of this Agreement is found by a court of competent jurisdiction to be unenforceable, that provision shall be severed and the remainder of this Agreement shall continue in full force and effect. 

14. Complete Understanding; Modification. 

This Agreement, including the Exhibits mentioned herein, and the Employment Agreement constitute the final, exclusive and complete
understanding and agreement of the Parties hereto and supersede all prior understandings and agreements with respect to the subject matter hereof. Any waiver, modification or amendment of any provision of this Agreement shall be effective only if in
writing and signed by the Parties hereto. 
 15. Notices. 

Any notices required or permitted hereunder shall be given to the appropriate Party at the address listed on the first page of this Agreement,
or such other address as the Party shall specify in writing pursuant to this notice provision. Such notice shall be deemed given upon personal delivery to the appropriate address or three days after the date of mailing if sent by certified or
registered mail. 

 16. Counterparts. 

This Agreement may be executed in one or more counterparts each of which will be deemed an original, but all of which together shall constitute
one and the same instrument. 

 IN WITNESS WHEREOF, the
Parties hereto have executed this Scientific Advisor Agreement as of the date first written above. 
  

									
	ZOSANO PHARMA CORPORATION	 		 	ADVISOR
				
	By:	 	/s/ Vikram Lamba	 		 	 /s/ Peter Daddona

		 	Name:  Vikram Lamba	 		 	Peter Daddona
		 	Title:    Chief Executive Officer	 		 	

  

							
	ZP OPCO, INC.	 		 	
		 		 	
	By:	 	 /s/ Vikram Lamba
	 		 	
		 	Name:  Vikram Lamba	 		 	
		 	Title:    Chief Executive Officer	 		 	

  

 EXHIBIT A 

SCOPE AND COMPENSATION 

1. Services: Advisor shall perform scientific advisory services as requested by the Company, including without limitation: 

 

	 	•	 	Support senior executives of the Company in connection with the management of the Company research and development operations; 

  

	 	•	 	Support senior executives of the Company in connection with developing, acquiring, protecting, licensing and enforcing intellectual property rights; 

 

	 	•	 	Support senior executives of the Company in connection with strategy and tactics for obtaining from regulators, inside and outside of the U.S., permission to conduct clinical trials of Company products and to
commercialize products; 

  

	 	•	 	Provide advice regarding the Company’s research and development and intellectual property strategies; 

  

	 	•	 	Provide scientific advice and services; and 

  

	 	•	 	Provide advice to the CEO and CSO regarding the selection of, and performance of, members of the Company’s scientific advisory board and the Company’s research and development personnel. 

2. Consideration: 
 (a)
Subject to Section 2(b), the Company will compensate Advisor at the rate of $4,000 per month for all Services performed and invoiced under this Agreement. On a monthly basis, Advisor shall submit to the Company a written invoice for services
performed under this Agreement, which lists the dates that such services were performed. The Company will pay such invoices promptly following receipt, subject to the approval of an authorized representative of the Company. 

(b) In the event that (i) the Company requests that the Consultant travel on its behalf (e.g., to attend a meeting with the FDA),
(ii) the Consultant agrees to the request, and (iii) the trip causes him to provide more than eight hours of Services in a given month, then the Company shall pay him at a rate $500 per hour for each such excess hour, subject to a maximum
fee of $2,500 day (plus reimbursement of expenses, as provided below). 
 3. Expenses that will be reimbursed: The Company
shall reimburse Advisor for business expenses that are reasonable and necessary for Advisor to perform, and were incurred by Advisor in the course of the performance of Advisor’s duties pursuant to this Agreement and in accordance with the
Company’s general policies. Such expenses shall be reimbursed upon Advisor’s submission of vouchers and an expense report in such form as may be required by the Company consistent with the Company’s policies in place from
time-to-time.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]